These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 1429406

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder.
    Storch EA, Merlo LJ, Larson MJ, Bloss CS, Geffken GR, Jacob ML, Murphy TK, Goodman WK.
    Acta Psychiatr Scand; 2008 Jan; 117(1):67-75. PubMed ID: 17986317
    [Abstract] [Full Text] [Related]

  • 23. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.
    Sayyah M, Boostani H, Pakseresht S, Malayeri A.
    Psychiatry Res; 2011 Oct 30; 189(3):403-6. PubMed ID: 21329988
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A, Rosenthal J, Nezu A, Winston A.
    Mt Sinai J Med; 1990 Nov 30; 57(6):348-52. PubMed ID: 2079952
    [Abstract] [Full Text] [Related]

  • 25. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG, Fluoxetine Pediatric OCD Study Team.
    J Am Acad Child Adolesc Psychiatry; 2001 Jul 30; 40(7):773-9. PubMed ID: 11437015
    [Abstract] [Full Text] [Related]

  • 26. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK, Brennan EM, Johnco C, Parker-Athill EC, Miladinovic B, Storch EA, Lewin AB.
    J Child Adolesc Psychopharmacol; 2017 Sep 30; 27(7):640-651. PubMed ID: 28358599
    [Abstract] [Full Text] [Related]

  • 27. Fluoxetine for childhood anxiety disorders.
    Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M.
    J Am Acad Child Adolesc Psychiatry; 1994 Sep 30; 33(7):993-9. PubMed ID: 7961355
    [Abstract] [Full Text] [Related]

  • 28. Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.
    Maneeton N, Maneeton B, Karawekpanyawong N, Woottiluk P, Putthisri S, Srisurapanon M.
    Nord J Psychiatry; 2020 Oct 30; 74(7):461-469. PubMed ID: 32242450
    [Abstract] [Full Text] [Related]

  • 29. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
    Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E.
    Compr Psychiatry; 2010 Oct 30; 51(4):373-9. PubMed ID: 20579510
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH.
    J Child Adolesc Psychopharmacol; 2020 Feb 30; 30(1):32-37. PubMed ID: 31800306
    [Abstract] [Full Text] [Related]

  • 32. Fluoxetine treatment of children and adults with autistic disorder and mental retardation.
    Cook EH, Rowlett R, Jaselskis C, Leventhal BL.
    J Am Acad Child Adolesc Psychiatry; 1992 Jul 30; 31(4):739-45. PubMed ID: 1644739
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S.
    J Psychiatr Res; 2013 Feb 30; 47(2):175-80. PubMed ID: 23063327
    [Abstract] [Full Text] [Related]

  • 35. Manual-Driven group cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a pilot study.
    Thienemann M, Martin J, Cregger B, Thompson HB, Dyer-Friedman J.
    J Am Acad Child Adolesc Psychiatry; 2001 Nov 30; 40(11):1254-60. PubMed ID: 11699798
    [Abstract] [Full Text] [Related]

  • 36. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment.
    King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L.
    J Am Acad Child Adolesc Psychiatry; 1991 Mar 30; 30(2):179-86. PubMed ID: 2016219
    [Abstract] [Full Text] [Related]

  • 37. Peer victimization in children with obsessive-compulsive disorder: relations with symptoms of psychopathology.
    Storch EA, Ledley DR, Lewin AB, Murphy TK, Johns NB, Goodman WK, Geffken GR.
    J Clin Child Adolesc Psychol; 2006 Sep 30; 35(3):446-55. PubMed ID: 16836482
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
    Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky HG.
    Wien Klin Wochenschr; 1999 Jun 04; 111(11):439-42. PubMed ID: 10420495
    [Abstract] [Full Text] [Related]

  • 39. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents.
    Alderman J, Wolkow R, Fogel IM.
    J Child Adolesc Psychopharmacol; 2006 Jun 04; 16(1-2):117-29. PubMed ID: 16553533
    [Abstract] [Full Text] [Related]

  • 40. [Factor structure and reliability of the Spanish adaptation of the Children's Yale-Brown Obsessive-Compulsive Scale--Self Report (CY-BOCS-SR)].
    Godoy A, Gavino A, Valderrama L, Quintero C, Cobos MP, Casado Y, Sosa MD, Capafons JI.
    Psicothema; 2011 Apr 04; 23(2):330-5. PubMed ID: 21504689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.